CHV Capital

CHV Capital is the dedicated venture capital platform of Indiana University Health, functioning as a strategic investment arm rather than a standalone fund manager. It invests IU Health's balance-sheet capital directly into companies whose products can be deployed, piloted, or validated within the IU Health clinical system. This corporate-venture structure means CHV does not have external limited partners or a mandated fund-return timeline.

No. While CHV Capital is rooted in the Indiana life-sciences ecosystem and has close ties to regional research institutions, the firm invests nationally in health-technology companies that can derive strategic value from a relationship with IU Health's clinical and operational infrastructure. Portfolio company pilots and clinical validation studies frequently occur inside IU Health facilities regardless of the company's headquarters.

The IU Health affiliation gives CHV Capital a distinctive due-diligence and value-creation capability: companies can be evaluated by practicing clinicians, tested in real patient-care settings, and introduced to a concentrated base of potential enterprise customers. This clinical-integration model is rare among early-stage health-tech investors and functions as CHV Capital's primary sourcing and selection moat.

CHV Capital typically takes an active role in early-stage financings, often leading or co-leading seed and Series A rounds alongside specialized digital health and medtech venture firms. In later-stage rounds, the firm may co-invest where there is a strategic pilot or enterprise-adoption pathway through IU Health.

The firm focuses primarily on early-stage companies — seed through Series B — with an emphasis on opportunities where clinical validation and health-system adoption are the next critical milestones. This aligns with the point at which IU Health's clinical-testing infrastructure provides the greatest strategic advantage.